Liquid Crystalline Lipid Nanoparticles: Emerging Trends and Applications in Skin Cancer.

Q2 Pharmacology, Toxicology and Pharmaceutics Pharmaceutical nanotechnology Pub Date : 2024-08-30 DOI:10.2174/0122117385312450240816055942

Kamya Varshney, Rupa Mazumder, Anjna Rani, Pratibha Pandey, Malakapogu Ravindra Babu

{"title":"Liquid Crystalline Lipid Nanoparticles: Emerging Trends and Applications in Skin Cancer.","authors":"Kamya Varshney, Rupa Mazumder, Anjna Rani, Pratibha Pandey, Malakapogu Ravindra Babu","doi":"10.2174/0122117385312450240816055942","DOIUrl":null,"url":null,"abstract":"<p><p>Liquid crystalline lipid nanoparticles (LCNPs) represent a type of membrane-based nano-carriers formed through the self-assembly of lyotropic lipids. These lipids, such as unsaturated monoglycerides, phospholipids, and co-lipids, create liquid crystals or vesicles with an aqueous core enclosed by a natural or synthetic phospholipid bilayer upon exposure to an aqueous medium. Liquid crystalline lipid nanoparticles (LCNPs), akin to liposomes, have garnered significant attention as nanocarriers suitable for a diverse range of hydrophobic and hydrophilic molecules. Their notable structural advantage lies in a mono-channel network organization and the presence of multiple compartments, resulting in heightened encapsulation efficiency for various substances. Cubosomes, spongosomes, hexosomes, and multicompartment nanoparticles are examples of lipid nanocarriers with interior liquid crystalline structures that have recently gained a lot of interest as effective drug delivery systems. Additionally, LCNPs facilitate the sustained release of encapsulated compounds, including therapeutic macromolecules. This review delves into the structure of liquid crystalline lipid nanoparticles, explores preparation techniques, and outlines their applications in the context of skin cancer.</p>","PeriodicalId":19774,"journal":{"name":"Pharmaceutical nanotechnology","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmaceutical nanotechnology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0122117385312450240816055942","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 0

Abstract

Liquid crystalline lipid nanoparticles (LCNPs) represent a type of membrane-based nano-carriers formed through the self-assembly of lyotropic lipids. These lipids, such as unsaturated monoglycerides, phospholipids, and co-lipids, create liquid crystals or vesicles with an aqueous core enclosed by a natural or synthetic phospholipid bilayer upon exposure to an aqueous medium. Liquid crystalline lipid nanoparticles (LCNPs), akin to liposomes, have garnered significant attention as nanocarriers suitable for a diverse range of hydrophobic and hydrophilic molecules. Their notable structural advantage lies in a mono-channel network organization and the presence of multiple compartments, resulting in heightened encapsulation efficiency for various substances. Cubosomes, spongosomes, hexosomes, and multicompartment nanoparticles are examples of lipid nanocarriers with interior liquid crystalline structures that have recently gained a lot of interest as effective drug delivery systems. Additionally, LCNPs facilitate the sustained release of encapsulated compounds, including therapeutic macromolecules. This review delves into the structure of liquid crystalline lipid nanoparticles, explores preparation techniques, and outlines their applications in the context of skin cancer.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

液晶脂质纳米颗粒：皮肤癌的新趋势和应用。

液晶脂质纳米粒子（LCNPs）是一种基于膜的纳米载体，通过溶解性脂质的自组装形成。这些脂质（如不饱和单甘酯、磷脂和辅脂）在暴露于水性介质后会形成液晶或囊泡，其水性核心由天然或合成磷脂双分子层包裹。液晶脂质纳米粒子（LCNPs）类似于脂质体，作为适用于各种疏水性和亲水性分子的纳米载体，已经引起了广泛关注。其显著的结构优势在于单通道网络组织和多个隔室的存在，从而提高了对各种物质的封装效率。立方体、海绵体、六方体和多隔室纳米粒子都是具有内部液晶结构的脂质纳米载体，它们作为有效的给药系统最近受到了广泛关注。此外，LCNPs 还能促进封装化合物（包括治疗性大分子）的持续释放。这篇综述深入探讨了液晶脂质纳米粒子的结构，探讨了制备技术，并概述了它们在皮肤癌方面的应用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Pharmaceutical nanotechnology Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science

CiteScore

4.20

自引率

0.00%

发文量

期刊介绍： Pharmaceutical Nanotechnology publishes original manuscripts, full-length/mini reviews, thematic issues, rapid technical notes and commentaries that provide insights into the synthesis, characterisation and pharmaceutical (or diagnostic) application of materials at the nanoscale. The nanoscale is defined as a size range of below 1 µm. Scientific findings related to micro and macro systems with functionality residing within features defined at the nanoscale are also within the scope of the journal. Manuscripts detailing the synthesis, exhaustive characterisation, biological evaluation, clinical testing and/ or toxicological assessment of nanomaterials are of particular interest to the journal’s readership. Articles should be self contained, centred around a well founded hypothesis and should aim to showcase the pharmaceutical/ diagnostic implications of the nanotechnology approach. Manuscripts should aim, wherever possible, to demonstrate the in vivo impact of any nanotechnological intervention. As reducing a material to the nanoscale is capable of fundamentally altering the material’s properties, the journal’s readership is particularly interested in new characterisation techniques and the advanced properties that originate from this size reduction. Both bottom up and top down approaches to the realisation of nanomaterials lie within the scope of the journal.